Skip to main content
  • Saved

made a Post

Successful Anti-CLL1 CAR T-Cell Therapy in Secondary Acute Myeloid Leukemia

Successful Anti-CLL1 CAR T-Cell Therapy in Secondary Acute Myeloid Leukemia

Source :

https://doi.org/10.3389/fonc.2020.00685

Secondary acute myeloid leukemia (sAML) is a high-risk AML evolving from heterogenous prior hematological disorders. Compared to de novo AML, sAML has even worse responses to current therapy and thus is associated with lower remission rates, inferior overall survival (OS) and higher relapse rates.